Table 2 Outcome of thoracic radiotherapy based on EGFR expression, EML4-ALK rearrangement, and treatment modalities

Early response

Reduction in long diameter

EGFR positive (n = 42)

0.99

0.41 ± 0.19

0.02–0.79

0.04

EGFR negative (n = 45)

0.58

Reduction in short diameter

EGFR positive (n = 42)

0.64

0.17 ± 0.21

−0.25–0.59

0.42

EGFR negative (n = 45)

0.47

Late response

Reduction in long diameter

EGFR positive (n = 42)

1.30

0.33 ± 0.27

−0.21–0.87

0.23

EGFR negative (n = 45)

0.97

Reduction in short diameter

EGFR positive (n = 42)

1.35

0.59 ± 0.28

0.03–1.15

0.04

EGFR negative (n = 45)

0.76

Early response

Reduction in long diameter

ALK positive (n = 7)

0.23

0.21 ± 0.27

−0.78–0.36

0.45

ALK negative (n = 15)

0.44

Reduction in short diameter

ALK positive (n = 7)

0.16

0.34 ± 0.36

−1.08–0.42

0.37

ALK negative (n = 15)

0.49

Late response

Reduction in long diameter

ALK positive (n = 7)

0.72

0.36 ± 0.42

1.25–0.53

0.40

ALK negative (n = 15)

1.08

Reduction in short diameter

ALK positive (n = 7)

0.66

0.18 ± 0.53

−1.32–0.95

0.74

ALK negative (n = 15)

0.80

Early response

Reduction in long diameter

RT (n = 54)

0.55

−0.34 ± 0.17

−0.68–0.01

0.05

RT Plus (n = 47)

0.89

Reduction in short diameter

RT (n = 54)

0.41

−0.19 ± 0.18

−0.16–0.56

0.27

RT Plus (n = 47)

0. 61

Late response

Reduction in long diameter

RT (n = 54)

0.92

0.42 ± 0.26

−0.09–0.94

0.10

RT Plus (n = 47)

1.34

Reduction in short diameter

RT (n = 54)

0.74

0.27 ± 0.23

−0.73–0.19

0.24

RT Plus (n = 47)

1.02

Early response

Reduction in long diameter

EGFR positive (n = 42)

0.99

0.76 ± 0.42

−0.07–1.60

0.07

ALK positive (n = 7)

0.23

Reduction in short diameter

EGFR positive (n = 42)

0.64

−0.48 ± 0.41

−1.32–0.35

0.25

ALK positive (n = 7)

0.16

Late response

Reduction in long diameter

EGFR positive (n = 42)

1.30

0.58 ± 0.49

−0.42–1.59

0.25

ALK positive (n = 7)

0.72

Reduction in short diameter

EGFR positive (n = 42)

1.35

−0.69 ± 0.58

−1.88–0.50

0.25

ALK positive (n = 7)

0.66

Early response

Reduction in long diameter

EGFR exon 21 (n = 28)

1.06

0.21 ± 0.39

−0.58–0.99

0.60

EGFR exon 19 (n = 14)

0.86

Reduction in short diameter

EGFR exon 21 (n = 28

0.73

0.22 ± 0.42

−0.65–1.01

0.60

EGFR exon 19 (n = 14)

0.51

Late response

Reduction in long diameter

EGFR exon 21 (n = 28)

1.35

0.12 ± 0.45

−0.80–1.05

0.79

EGFR exon 19 (n = 14)

1.23

Reduction in short diameter

EGFR exon 21 (n = 28)

1.65

0.99 ± 0.50

−0.06–2.05

0.06

EGFR exon 19 (n = 14)

0.65

Early response

Reduction in long diameter

EGFR exon 21 (n = 28)

1.06

0.48 ± 0.21

0.07–0.90

0.02

EGFR negative (= 45)

0.58

Reduction in short diameter

EGFR exon 21 (n = 28)

0.73

0.26 ± 0.23

−0.21–0.73

0.27

EGFR negative (= 45)

0.47

Late response

Reduction in long diameter

EGFR exon 21 (n = 28)

1.35

0.38 ± 0.29

−0.20–0.96

0.20

EGFR negative (= 45)

0.97

Reduction in short diameter

EGFR exon 21 (n = 28)

1.65

0.91 ± 0.32

0.27–1.55

0.01

EGFR negative (= 45)

0.76

Early response

Reduction in long diameter

EGFR exon 19 (n = 14)

0.86

0.28 ± 0.26

−0.25–0.79

0.29

EGFR negative (= 45)

0.58

Reduction in short diameter

EGFR exon 19 (n = 14)

0.51

0.04 ± 0.26

−0.48–0.56

0.88

EGFR negative (= 45)

0.47

Late response

Reduction in long diameter

EGFR exon 19 (n = 14)

1.23

0.26 ± 0.35

−0.45–0.96

0.47

EGFR negative (= 45)

0.97

Reduction in short diameter

EGFR exon 19 (n = 14)

0.65

−0.11 ± 0.27

−0.67–0.44

0.68

EGFR negative (= 45)

0.76